IDiyas

For the Inventor, By the Inventor

East Windsor, NJ, United States of America

Jeffrey John Letourneau

USPTO Granted Patents = 17 

 

Average Co-Inventor Count = 7.2

ph-index = 4

Forward Citations = 57(Granted Patents)


Company Filing History:

goldMedal5 out of 134 
 
Ligand Pharmaceuticals, Inc.
 patents
silverMedal4 out of 8 
 
Venenum Biodesign, LLC
 patents
bronzeMedal4 out of 101 
 
Pharmacopeia Inc.
 patents
4. 3 out of 101 
 
N.v. Organon
 patents
5. 2 out of 3,681 
 
Bristol-myers Squibb Compnay
 patents
6. 1 out of 1 
 
Pharmacopela Drug Discovery, Inc.
 patent
where one patent can have more than one assignee

Years Active: 2005-2023

Loading Chart...
Loading Chart...
17 patents (USPTO):Explore Patents
1. 11773110 - Heterocycle amines and uses thereof (2023-10-03),
2. 11583538 - Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors (2023-02-21),
3. 11306098 - Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors (2022-04-19),
4. 11236055 - Non-systemic TGR5 agonists (2022-02-01),
5. 11186593 - Heterocycle amines and uses thereof (2021-11-30),
6. 10669242 - toxin inhibitors (2020-06-02),
7. 10604533 - Heterocycle amines and uses thereof (2020-03-31),
8. 10030034 - Heterocycle amines and uses thereof (2018-07-24),
9. 9266874 - Heterocycle amines and uses thereof (2016-02-23),
10. 8350043 - Azinone and diazinone V3 inhibitors for depression and stress disorders (2013-01-08),
11. 7906504 - [object Object] (2011-03-15),
12. 7820649 - Quinazolinone and isoquinolinone acetamide derivatives (2010-10-26),
13. 7807686 - 2-(4-oxo-4H-quinazolin-3-yl)acetamides and their use as vasopressin V3 antagonists (2010-10-05),
14. 7479495 - N-heterocyclic inhibitors of TNF-α expression (2009-01-20),
15. 7365209 - Nitrogen heterocycle biaryls for osteoporosis and other diseases (2008-04-29),

Title: The Innovative Contributions of Jeffrey John Letourneau

Introduction

Jeffrey John Letourneau is a prominent inventor based in East Windsor, NJ (US). He has made significant contributions to the fields of chemistry and medicine, holding a total of 17 patents. His work focuses on developing compounds and methods that address various medical challenges.

Latest Patents

Among his latest patents, Letourneau has developed heterocycle amines and their uses. These compounds and methods are disclosed for their potential applications in treating inflammatory disorders. Another notable invention involves substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines, which serve as TREX1 inhibitors. These compounds are designed to modulate the TREX1 protein, making them valuable for treating or preventing disorders influenced by TREX1 inhibition.

Career Highlights

Throughout his career, Letourneau has worked with reputable companies such as Ligand Pharmaceuticals, Inc. and Venenum Biodesign, LLC. His experience in these organizations has allowed him to further his research and development efforts in innovative medicinal chemistry.

Collaborations

Letourneau has collaborated with notable colleagues, including Koc-Kan Ho and Brian F McGuinness. These partnerships have contributed to the advancement of his research and the successful development of his patented inventions.

Conclusion

Jeffrey John Letourneau's innovative work in the field of chemistry and medicine has led to the development of numerous patents that hold promise for treating various medical conditions. His contributions continue to impact the scientific community positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…